miRagen Therapeutics
As of the edition of 20 October 2026, miRagen Therapeutics runs 5 drugs, 1 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
miRagen Therapeutics was merged in 2020.
The records place 2 company names in this family.
- miRagen Therapeutics, Inc.: merged in 2020
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Veligrotug | Ends 2038 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| IGF1R Insulin-like growth factor 1 receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where miRagen Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 12 trials led
- Eye: 9 trials led
- Hormones: 9 trials led